HUTCHINSON, Minn. (AFX) - Computer and medical device maker Hutchinson Technology Inc. said Thursday the U.S. Food and Drug Administration approved its tissue oxygenation monitor.
The device, called the InSpectra St02 Tissue Oxygenation Monitor, uses near infrared technology to monitor tissue oxygen saturation. It is aimed at the trauma care market for use in monitoring patients being treated for hemorrhagic shock, a condition that results when a large amount blood loss makes it difficult for enough oxygen to be delivered through the body.
The company plans to launch the product at the annual meeting of the American Association for Surgery of Trauma, which is scheduled to begin Sept. 28.
Aside from the medical monitor, the company's other focus is on developing suspension assemblies for hard disk drives.
Shares of Hutchinson, which also reported its third-quarter results after the bell, fell $2.87, or 14.3 percent, to $17.21 in aftermarket trading on the INET electronic exchange, from their close at $20.08 on the Nasdaq.
Copyright 2006 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.